

DOCKET NO.: CP380C
Application No.: 10/649,776
Office Action Dated: December 15, 2005

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A method of treating melanoma in a human, which comprises administering parenterally a therapeutically effective amount of ~~one or more arsenic compounds~~ arsenic trioxide to said human.
2. (canceled)
3. (currently amended) The method of ~~claim 2~~ claim 1, wherein said arsenic trioxide is formulated as an ionic aqueous solution.
4. (original) The method of claim 1, wherein the total daily amount administered is from about 10 µg to about 200 mg.
5. (original) The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 150 mg.
6. (original) The method of claim 1, wherein the total daily amount administered is from about 0.5 mg to about 70 mg.
7. (currently amended) The method of claim 1, wherein the arsenic ~~compound~~ trioxide is administered intravenously.
8. (currently amended) The method of claim 1, wherein the arsenic ~~compound~~ trioxide is administered in combination with an effective amount of at least one other therapeutic.
9. (original) The method of claim 8, wherein the other therapeutic agent is a chemotherapeutic or radiotherapeutic.

DOCKET NO.: CP380C
Application No.: 10/649,776
Office Action Dated: December 15, 2005

PATENT

10. (original) The method of claim 8, wherein the other therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.

11. (canceled)